Answers are grounded in this paper and cite their sources.
Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.
No takes yet. Share an insight, caveat, or question.
Ramírez et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: